Literature DB >> 21647193

Local treatment of metastatic cancer--killing the seed or disturbing the soil?

Scott C Morgan1, Chris C Parker.   

Abstract

The fact that local therapy of the primary tumor is futile in the presence of metastatic disease is almost considered axiomatic among oncologists. However, this perception is now being challenged by new laboratory and clinical data. Results from animal models have demonstrated that some primary tumors release factors that enter the circulation which, by mobilizing cells from bone marrow, render distant organs more receptive to metastasis. Clinical observations in renal, breast, and prostate cancer are all consistent with the hypothesis that treatment directed against the primary tumor might retard progression of existing metastases. This hypothesis is amenable to testing by randomized trials of local therapy to the primary site in patients with metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647193     DOI: 10.1038/nrclinonc.2011.88

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  27 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Removing the primary tumor after the cancer has spread.

Authors:  I F Tannock
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma.

Authors:  M Lahn; P Fisch; G Köhler; R Kunzmann; I Hentrich; H Jesuiter; D Behringer; B Muschal; H Veelken; P Kulmburg; D N Iklé; A Lindemann
Journal:  Eur Urol       Date:  1999-01       Impact factor: 20.096

4.  The distribution of secondary growths in cancer of the breast. 1889.

Authors:  S Paget
Journal:  Cancer Metastasis Rev       Date:  1989-08       Impact factor: 9.264

5.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 6.  Clinical implications of cancer self-seeding.

Authors:  Elizabeth Comen; Larry Norton; Joan Massagué
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

7.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

8.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors:  Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.

Authors:  Janine T Erler; Kevin L Bennewith; Thomas R Cox; Georgina Lang; Demelza Bird; Albert Koong; Quynh-Thu Le; Amato J Giaccia
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

10.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

Authors:  Rosandra N Kaplan; Rebecca D Riba; Stergios Zacharoulis; Anna H Bramley; Loïc Vincent; Carla Costa; Daniel D MacDonald; David K Jin; Koji Shido; Scott A Kerns; Zhenping Zhu; Daniel Hicklin; Yan Wu; Jeffrey L Port; Nasser Altorki; Elisa R Port; Davide Ruggero; Sergey V Shmelkov; Kristian K Jensen; Shahin Rafii; David Lyden
Journal:  Nature       Date:  2005-12-08       Impact factor: 49.962

View more
  19 in total

1.  Lung cancer cells induce senescence and apoptosis of pleural mesothelial cells via transforming growth factor-beta1.

Authors:  Zhi-Feng Miao; Wen-Ya Li; Zhen-Ning Wang; Ting-Ting Zhao; Ying-Ying Xu; Yong-Xi Song; Jin-Yu Huang; Hui-Mian Xu
Journal:  Tumour Biol       Date:  2014-11-30

Review 2.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

Review 3.  The Emerging Role of Local Therapy in Metastatic Prostate Cancer.

Authors:  Nora Sundahl; Alison Tree; Chris Parker
Journal:  Curr Oncol Rep       Date:  2020-01-20       Impact factor: 5.075

Review 4.  Clinical considerations for working with patients with advanced cancer.

Authors:  Megan Taylor-Ford
Journal:  J Clin Psychol Med Settings       Date:  2014-09

5.  Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo.

Authors:  Thambi Dorai; Janane Diouri; Orla O'Shea; Stephen B Doty
Journal:  J Cancer Ther       Date:  2014-04-01

6.  Deterministic separation of cancer cells from blood at 10 mL/min.

Authors:  Kevin Loutherback; Joseph D'Silva; Liyu Liu; Amy Wu; Robert H Austin; James C Sturm
Journal:  AIP Adv       Date:  2012-10-03       Impact factor: 1.548

7.  Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients.

Authors:  Eran Sadot; Ser Yee Lee; Constantinos T Sofocleous; Stephen B Solomon; Mithat Gönen; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Clifford A Hudis; Michael I D'Angelica
Journal:  Ann Surg       Date:  2016-07       Impact factor: 12.969

8.  Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer.

Authors:  Scott C Morgan; Oliver E Holmes; Julia Craig; Scott Grimes; Shawn Malone
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-05       Impact factor: 5.554

9.  Denosumab: a new option in the treatment of bone metastases from urological cancers.

Authors:  Takeshi Yuasa; Shinya Yamamoto; Shinji Urakami; Iwao Fukui; Junji Yonese
Journal:  Onco Targets Ther       Date:  2012-09-21       Impact factor: 4.147

10.  Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles.

Authors:  Xingfang Su; Nicole Yang; K Dane Wittrup; Darrell J Irvine
Journal:  Biomacromolecules       Date:  2013-03-11       Impact factor: 6.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.